Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Recurrence 1Neoplasms 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 35Rituximab 33venetoclax 24ibrutinib 14Vincristine 14Prednisone 14Doxorubicin 14Gemcitabine 13pembrolizumab 12fludarabine 12Bendamustine Hydrochloride 11Etoposide 10obinutuzumab 9Filgrastim 9Dexamethasone 9Bortezomib 9fludarabine phosphate 8Mycophenolic Acid 8Drug Therapy 8ofatumumab 7Whole-Body Irradiation 7Sirolimus 7Peripheral Blood Stem Cell Transplantation 7Methotrexate 7Busulfan 7Therapeutics 6Radiotherapy 6Mesna 6Lenalidomide 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × fluoroazomycin arabinoside × Lymphoid × Clear all
NCT04409314 2023-08-21

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

University of California, San Francisco

Completed
23 enrolled
LymphoidPlasma cell

Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡